Medication info
Megapolmin Extended-Release 500 mg (Metformin Hydrochloride)

Megapolmin Extended-Release 500 mg (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hanmi Pharmaceutical Co., Ltd.
Appearance
White to pale yellow oblong tablets
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200502201 · Approved 2005.12.14 · Insurance code 643500840

Summary

Main use
Treatment of type 2 diabetes in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on response to and tolerability of the medicine and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. Up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During treatment initiation and dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or concomitantly with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, using the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Hanmi Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used for adult patients with type 2 diabetes whose blood sugar control is insufficient with diet and exercise alone, especially if they are overweight. It helps to control blood sugar either alone or in combination with other oral hypoglycemic agents or insulin. This aids in stabilizing blood sugar levels and improving diabetes management.

How to take

Adult dose

The dose should be determined individually based on response to and tolerability of the medicine and should not exceed the recommended maximum daily dose. - The usual starting dose is one 500mg extended-release metformin hydrochloride tablet once daily with the evening meal. - Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. - When increasing the dose, increase by 500mg each week. Up to a maximum of 2000mg per day may be taken with the evening meal. If glycemic control is not achieved with up to 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. - For patients already being treated with metformin tablets, the initial dose of this preparation is the same as the daily dose of immediate-release metformin tablets. Switching to this preparation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. - During treatment initiation and dose adjustment, fasting blood glucose should be measured to assess response to this medicine and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. - The goal of treatment with this medicine, whether administered as monotherapy or concomitantly with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This medicine may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, using the following dose adjustment. - The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, this medicine should be discontinued immediately.

Precautions

This drug can rarely cause a serious condition known as lactic acidosis, which can be life-threatening. Caution should be exercised when using this medication with other diabetes treatments as hypoglycemia may occur. This drug should not be used in patients with moderate to severe renal impairment or those with dehydration, serious infections, or heart disease. Patients with acute heart failure or those receiving iodinated contrast media should also not use this medication. Patients with hypersensitivity to this drug or with type 1 diabetes or diabetic ketoacidosis should not be administered this drug. Patients with severe infections, trauma, or undergoing surgery should temporarily stop taking this drug until their condition stabilizes. Patients with poor nutritional status, liver dysfunction, excessive alcohol consumption, or symptoms of dehydration should also use this drug with caution. Renal function should be regularly monitored, and the drug should be discontinued if renal function declines. During treatment, there is a risk of hypoglycemia or lactic acidosis due to irregular meals, excessive exercise, and interactions with other drugs, so caution is advised. Gastrointestinal disturbances may commonly occur when starting the medication; gradually increasing the dosage or taking it with meals can help reduce the symptoms. This drug may cause vitamin B12 deficiency, so it is recommended to regularly check serum vitamin B12 levels. Alcohol may increase the risk of side effects from this drug, thus it is advisable to avoid drinking during treatment. During pregnancy, it should only be used in special cases, and fetal growth should be closely monitored. Breastfeeding women should be careful as this drug is excreted in breast milk and should consider whether to continue breastfeeding or stop medication. Elderly patients are at greater risk for renal function decline and need dosage adjustments and regular renal function tests. In case of overdose, the risk is lactic acidosis rather than hypoglycemia, and blood dialysis may be necessary to remove the drug if needed. This medication should be swallowed whole without chewing or crushing, and it is normal for the tablet coating to be excreted in the stool. While taking this medication, regular monitoring of blood sugar, renal function, and hematological tests should be conducted, and any abnormal symptoms should be reported to healthcare providers immediately.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • anorexia
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering, and it is recommended to keep it in a cool place at a temperature below 25 degrees Celsius. Storing it this way will help maintain the drug's effectiveness for a longer time.

Appearance and packaging

Appearance

White to pale yellow oblong tablets

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.